• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Walgreens Boots Alliance Inc.

    5/28/25 5:00:29 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $WBA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 21)


    CENCORA, INC.

    (Name of Issuer)


    Common Stock, par value $0.01 per share

    (Title of Class of Securities)


    03073E105

    (CUSIP Number)


    Lillian Tsu
    Cleary Gottlieb Steen & Hamilton LLP , One Liberty Plaza
    New York, NY, 10006
    (212) 225-2000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    05/27/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    03073E105


    1 Name of reporting person

    Walgreens Boots Alliance Holdings LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF, OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    8Shared Voting Power

    10,380,000.00
    9Sole Dispositive Power

    10Shared Dispositive Power

    10,380,000.00
    11Aggregate amount beneficially owned by each reporting person

    10,380,000.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    5.4 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    * This calculation is based on 193,823,487 shares of Common Stock outstanding as of April 30, 2025 (as reported by the Issuer in its Quarterly Report on Form 10-Q filed on May 7, 2025).


    SCHEDULE 13D

    CUSIP No.
    03073E105


    1 Name of reporting person

    WBA Investments, Inc.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF, OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    8Shared Voting Power

    10,380,000.00
    9Sole Dispositive Power

    10Shared Dispositive Power

    10,380,000.00
    11Aggregate amount beneficially owned by each reporting person

    10,380,000.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    5.4 %
    14Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:
    * This calculation is based on 193,823,487 shares of Common Stock outstanding as of April 30, 2025 (as reported by the Issuer in its Quarterly Report on Form 10-Q filed on May 7, 2025).


    SCHEDULE 13D

    CUSIP No.
    03073E105


    1 Name of reporting person

    Walgreens Boots Alliance, Inc.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF, OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    8Shared Voting Power

    10,380,000.00
    9Sole Dispositive Power

    10Shared Dispositive Power

    10,380,000.00
    11Aggregate amount beneficially owned by each reporting person

    10,380,000.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    5.4 %
    14Type of Reporting Person (See Instructions)

    HC, CO

    Comment for Type of Reporting Person:
    * This calculation is based on 193,823,487 shares of Common Stock outstanding as of April 30, 2025 (as reported by the Issuer in its Quarterly Report on Form 10-Q filed on May 7, 2025).


    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, par value $0.01 per share
    (b)Name of Issuer:

    CENCORA, INC.
    (c)Address of Issuer's Principal Executive Offices:

    Lanesha Minnix, EVP/Global CLO Walgreens, Boots Alliance, Inc. 108 Wilmot Road, Deerfield, ILLINOIS , 60015.
    Item 1 Comment:
    This Amendment No. 21 to Schedule 13D (this "Amendment No. 21") amends and supplements the Schedule 13D (the "Schedule 13D") relating to the common stock, $0.01 par value per share ("Common Stock"), of Cencora, Inc., a Delaware corporation (the "Issuer"), originally filed with the Securities and Exchange Commission (the "SEC") on April 15, 2014, as amended by Amendment No. 1 thereto filed on January 16, 2015, Amendment No. 2 thereto filed on January 25, 2016, Amendment No. 3 thereto filed on March 22, 2016, Amendment No. 4 thereto filed on August 25, 2016, Amendment No. 5 thereto filed on November 14, 2016, Amendment No. 6 thereto filed on January 6, 2021, Amendment No. 7 thereto filed on June 3, 2021, Amendment No. 8 thereto filed on May 12, 2022, Amendment No. 9 thereto filed on August 4, 2022, Amendment No. 10 thereto filed on November 9, 2022, Amendment No. 11 thereto filed on December 12, 2022, Amendment No. 12 thereto filed on May 15, 2023, Amendment No. 13 thereto filed on June 20, 2023, Amendment No. 14 thereto filed on August 7, 2023, Amendment No. 15 thereto filed on November 14, 2023, Amendment No. 16 thereto filed on February 9, 2024, Amendment No. 17 thereto filed on August 5, 2024, Amendment No. 18 thereto filed on August 20, 2024, Amendment No. 19 thereto filed on February 10, 2025 and Amendment No. 20 thereto filed on March 25, 2025. Terms used but not defined in this Amendment No. 21 have the respective meanings given to such terms in the original Schedule 13D, as previously amended.
    Item 4.Purpose of Transaction
     
    Item 4 is amended and supplemented as follows by adding the following: Director Resignation In anticipation of the Reporting Person's ownership falling below 5% as a result of the scheduled settlement of certain prepaid variable share forward transactions which is expected to take place in early June, on May 27, 2025, Ornella Barra notified the Board of Directors of the Issuer of her decision to resign as a member of the Board, effective immediately. Ms. Barra's resignation is not due to any disagreement with the Issuer on any matter relating to the Issuer's operations, policies or practices. The Reporting Persons do not currently intend to exercise their rights pursuant to the Amended and Restated Shareholders Agreement by and between Walgreens Boots Alliance, Inc., and Cencora, Inc., dated as of June 1, 2021, to designate a director to fill the vacancy created by Ms. Barra's resignation.
    Item 7.Material to be Filed as Exhibits.
     
    Exhibits Description of Exhibits 99.1 Framework Agreement, dated as of March 18, 2013, by and among the Issuer, Walgreen Co. and Alliance Boots GmbH (filed as Exhibit 10.1 to the Issuer's Current Report on Form 8-K (File No. 001-16671), filed on March 20, 2013 and incorporated by reference herein). 99.2 Warrant issued on March 18, 2013 (filed as Exhibit 4.1 to the Issuer's Current Report on Form 8-K (File No. 001-16671), filed on March 20, 2013 and incorporated by reference herein).* 99.3 Warrant issued on March 18, 2013 (filed as Exhibit 4.2 to the Issuer's Current Report on Form 8-K (File No. 001-16671), filed on March 20, 2013 and incorporated by reference herein).* 99.4 Warrant issued on March 18, 2013 (filed as Exhibit 4.3 to the Issuer's Current Report on Form 8-K (File No. 001-16671), filed on March 20, 2013 and incorporated by reference herein).* 99.5 Amendment No. 1 dated August 25, 2016 to Warrant issued on March 18, 2013 (filed as Exhibit 4.1 to the Issuer's Current Report on Form 8-K (File No. 001-16671), filed on August 25, 2016 and incorporated by reference herein).* 99.6 Warrant issued on March 18, 2013 (filed as Exhibit 4.4 to the Issuer's Current Report on Form 8-K (File No. 001-16671), filed on March 20, 2013 and incorporated by reference herein).* 99.7 Amendment No. 1 dated August 25, 2016 to Warrant issued on March 18, 2013 (filed as Exhibit 4.2 to the Issuer's Current Report on Form 8-K (File No. 001-16671), filed on August 25, 2016 and incorporated by reference herein).* 99.8 Shareholders Agreement, dated as of March 18, 2013, by and among the Issuer, Walgreen Co. and Alliance Boots GmbH (filed as Exhibit 10.2 to the Issuer's Current Report on Form 8-K (File No. 001-16671), filed on March 20, 2013 and incorporated by reference herein). 99.9 Transaction Rights Agreement, dated as of March 18, 2013, by and among Walgreen Co., Walgreens Pharmacy Strategies, LLC, Alliance Boots GmbH, Alliance Boots Luxembourg S.a r.l., and WAB Holdings LLC (filed as Exhibit 10.3 to Walgreen Co.'s Current Report on Form 8-K (File No. 1-00604), filed on March 20, 2013 and incorporated by reference herein). 99.10 Notice, dated as of December 31, 2014, provided by Walgreen Co. to AmerisourceBergen Corporation and Alliance Boots GmbH (previously filed on January 16, 2015 as Exhibit 99.11 to Amendment No. 1 to this Schedule 13D). 99.11 Joint Filing Agreement, dated August 25, 2016 (previously filed on August 25, 2016 as Exhibit 99.11 to Amendment No. 4 to this Schedule 13D). 99.12 Share Purchase Agreement, dated as of January 6, 2021, by and between Walgreens Boots Alliance, Inc., and AmerisourceBergen Corporation (incorporated herein by reference to Exhibit 2.1 of the Form 8-K Filed by Walgreens Boots Alliance, Inc. on January 7, 2021 (file number 001-36759)). 99.13 Amended and Restated AmerisourceBergen Shareholders Agreement, dated as of June 1, 2021, by and between Walgreens Boots Alliance, Inc., and AmerisourceBergen Corporation (previously filed on June 3, 2021 as Exhibit 99.13 to Amendment No. 7 to this Schedule 13D). 99.14 Amendment No. 1 to the Amended and Restated AmerisourceBergen Shareholders Agreement, dated as of August 2, 2022, by and between Walgreens Boots Alliance, Inc., and Amerisource Bergen Corporation (filed as Exhibit 10.2 to the Issuer's Quarterly Report on Form 10-Q (File No. 001-16671), filed on August 3, 2022 and incorporated by reference herein). 99.15 Underwriting Agreement, dated as of November 7, 2022, by and among AmerisourceBergen Corporation, Walgreens Boots Alliance Holdings LLC and Morgan Stanley & Co. LLC (previously filed on November 9, 2022 as Exhibit 99.15 to Amendment No. 10 to this Schedule 13D). 99.16 Share Repurchase Agreement, dated as of November 6, 2022, by and between AmerisourceBergen Corporation and Walgreens Boots Alliance Holdings LLC (previously filed on November 9, 2022 as Exhibit 99.16 to Amendment No. 10 to this Schedule 13D). 99.17 Form of Lock-Up Agreement (included in Exhibit 99.15). 99.18 Share Repurchase Agreement, dated as of December 8, 2022, by and between AmerisourceBergen Corporation and Walgreens Boots Alliance Holdings LLC (filed as Exhibit 10.1 to the Issuer's Current Report on Form 8-K (File No. 001-16671), filed on December 12, 2022 and incorporated by reference herein). 99.19 Form of Master Confirmation: Pre-paid Variable Share Forward Transactions (previously filed on May 15, 2023 as Exhibit 99.19 to Amendment No. 12 to this Schedule 13D). 99.20 Share Repurchase Agreement, dated as of May 11, 2023, by and between AmerisourceBergen Corporation and Walgreens Boots Alliance Holdings LLC (filed as Exhibit 10.1 to the Issuer's Current Report on Form 8-K (File No. 001-16671), filed on May 15, 2023 and incorporated by reference herein). 99.21 Share Repurchase Agreement, dated as of June 15, 2023, by and between AmerisourceBergen Corporation and Walgreens Boots Alliance Holdings LLC (filed as Exhibit 10.1 to the Issuer's Current Report on Form 8-K (File No. 001-16671), filed on June 20, 2023 and incorporated by reference herein). 99.22 Underwriting Agreement, dated as of August 3, 2023, by and among AmerisourceBergen Corporation, Walgreens Boots Alliance Holdings LLC, Goldman Sachs & Co. LLC, Bank of America, N.A., Citibank, N.A., Deutsche Bank AG, London Branch, Goldman Sachs International, Mizuho Markets Americas LLC, Morgan Stanley Bank, N.A., Societe Generale and Wells Fargo Bank, National Association (previously filed on August 7, 2023 as Exhibit 99.22 to Amendment No. 14 to this Schedule 13D). 99.23 Form of Lock-Up Agreement (included in Exhibit 99.22). 99.24 Share Repurchase Agreement, dated as of August 2, 2023, by and between AmerisourceBergen Corporation and Walgreens Boots Alliance Holdings LLC (previously filed on August 7, 2023 as Exhibit 99.24 to Amendment No. 14 to this Schedule 13D). 99.25 Share Repurchase Agreement, dated as of November 9, 2023, by and between Cencora, Inc. and Walgreens Boots Alliance Holdings LLC (previously filed on November 14, 2023 as Exhibit 99.25 to Amendment No. 15 to this Schedule 13D). 99.26 Share Repurchase Agreement, dated as of February 7, 2024, by and between Cencora, Inc. and Walgreens Boots Alliance Holdings LLC (previously filed on February 9, 2024 as Exhibit 99.26 to Amendment No. 16 to this Schedule 13D). 99.27 Share Repurchase Agreement, dated as of May 22, 2024, by and between Cencora, Inc. and Walgreens Boots Alliance Holdings LLC (previously filed on August 5, 2024 as Exhibit 99.27 to Amendment No. 17 to this Schedule 13D). 99.28 Share Repurchase Agreement, dated as of August 1, 2024, by and between Cencora, Inc. and Walgreens Boots Alliance Holdings LLC (previously filed on August 5, 2024 as Exhibit 99.28 to Amendment No. 17 to this Schedule 13D). 99.29 Amendment No. 2 to the Amended and Restated Shareholders Agreement, dated as of August 16, 2024, by and between Walgreens Boots Alliance, Inc., and Cencora, Inc. (filed as Exhibit 10.2 to the Issuer's Current Report on Form 8-K (File No. 001-16671), filed on August 16, 2024 and incorporated by reference herein). 99.30 Share Repurchase Agreement, dated as of February 6, 2025, by and between Cencora, Inc. and Walgreens Boots Alliance Holdings LLC. * As previously disclosed, Warrants exercised in full on March 18, 2016 and August 25, 2016.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Walgreens Boots Alliance Holdings LLC
     
    Signature:/s/ Todd Heckman
    Name/Title:Todd Heckman/ President
    Date:05/28/2025
     
    WBA Investments, Inc.
     
    Signature:/s/ Todd Heckman
    Name/Title:Todd Heckman/ President
    Date:05/28/2025
     
    Walgreens Boots Alliance, Inc.
     
    Signature:/s/ Manmohan Mahajan
    Name/Title:Manmohan Mahajan/Executive Vice President and Global Chief Financial Officer
    Date:05/28/2025
    Get the next $WBA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $WBA

    DatePrice TargetRatingAnalyst
    2/28/2025$11.00 → $9.00Hold → Sell
    Deutsche Bank
    2/26/2024$23.00Market Perform
    Leerink Partners
    2/20/2024Hold → Reduce
    HSBC Securities
    1/3/2024$21.00Underweight
    Barclays
    12/22/2023$27.00Hold
    HSBC Securities
    10/23/2023$27.00 → $30.00Neutral → Overweight
    JP Morgan
    7/3/2023$37.00 → $27.00Underweight
    Morgan Stanley
    6/28/2023$46.00 → $34.00Buy → Hold
    Deutsche Bank
    More analyst ratings

    $WBA
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Walgreens Boots Alliance Inc.

      DEFA14A - Walgreens Boots Alliance, Inc. (0001618921) (Filer)

      6/17/25 4:05:47 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form DEFA14A filed by Walgreens Boots Alliance Inc.

      DEFA14A - Walgreens Boots Alliance, Inc. (0001618921) (Filer)

      6/13/25 4:05:18 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form DEFA14A filed by Walgreens Boots Alliance Inc.

      DEFA14A - Walgreens Boots Alliance, Inc. (0001618921) (Filer)

      6/12/25 4:24:00 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Global CLO & Corp. Sec. Minnix Lanesha covered exercise/tax liability with 19,135 shares, decreasing direct ownership by 5% to 348,093 units (SEC Form 4)

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      6/3/25 9:16:29 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • EVP, President U.S. Healthcare Langowksi Mary covered exercise/tax liability with 40,304 shares, decreasing direct ownership by 8% to 494,295 units (SEC Form 4)

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      6/3/25 9:12:39 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • EVP, Global Chief HR Officer Burger Elizabeth covered exercise/tax liability with 16,495 shares, decreasing direct ownership by 5% to 303,875 units (SEC Form 4)

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      6/3/25 9:08:21 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Executive Chairman of Board Pessina Stefano sold $9,163,161 worth of shares (832,258 units at $11.01) and bought $9,163,161 worth of shares (832,258 units at $11.01), decreasing direct ownership by 56% to 657,308 units (SEC Form 4)

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      4/29/25 8:49:21 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Bhandari Inderpal S bought $54,150 worth of shares (3,000 units at $18.05) (SEC Form 4)

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      4/15/24 5:45:26 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Mahajan Manmohan bought $116,280 worth of shares (6,000 units at $19.38) (SEC Form 4)

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      4/2/24 6:40:23 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • September 12, 2023 - FDA Issues Warning Letters to Firms Marketing Unapproved Eye Products

      For Immediate Release: September 12, 2023 The U.S. Food and Drug Administration has issued warning letters to eight companies for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law. These warning letters are part of the agency’s ongoing effort to protect Americans from potentially harmful ophthalmic products. Eye products addressed in the eight warning letters are illegal

      9/12/23 10:44:21 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples